• Japanese
  • Korean
  • Chinese
Cover Image

Circulating Tumor Cells (Ctcs) And Cancer Stem Cells (Cscs) Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018

Circulating tumor cell technology is an enabling technology for recovery and analysis of separated cancer cells in the peripheral blood. CTC technology offers advantages like high sensitivity, high specificity, reproducible, repeatable, and non-invasive diagnostic assay for guiding treatment decision and improved patient triage. Circulatory tumor cells (CTC) are cancer cells that get separated from the primary tumor or its metastases that circulate in the peripheral blood. Metastasis the major cause of cancer deaths and CTC may constitute seeds from metastases and indicate the spread of diseases. The circulating tumor cells' analysis will allow early detection of metastasis when it is less invasive. Molecular characterization of CTC enables the treatment to be planned effectively. Removing CTC from the blood will limit metastases after surgery or therapy.

Molecular characterization is significant from the point of view of developing new methodologies for CTC detection, isolation, enumeration, and subsequent genetic or proteomic analysis. Advancement in medical technologies is allowing efficient removal of CTC from circulation and has therapeutic potential.

This research report analyzes the Circulating tumor cells and cancer stem cells market from a technical as well as business perspective, describing the overall market size, industry growth rate, and market trends. It gives an analysis of the recent developments in CTC and CSC markets and includes detailed profiles of top industry players along with Porter's five force analysis. The report also analyzes all the micro and macro factors essential for the existing market players and new entrants along.

Major regions covered under this research study are North America, Europe, the Asia-Pacific, and the Rest of the World.

Reasons to Buy this Report

  • This research report will provide a forward perspective on market issues affecting market growth rate
  • It will help in understanding the competitive environment and make accurate and informed business decisions to withstand competition
  • The report will provide pin-point analysis of changing competition dynamics to keep one ahead of competitors
  • It will provide an in-depth analysis of key product segments and robust product segments
  • The research report provides a seven-year forecast on business projections and segmental behavior

Table of Contents

1. Introduction

  • 1.1. Key Objectives
  • 1.2. Report Description
  • 1.3. Scope and Definitions
  • 1.4. Research Methodology

2. Executive Summary

3. Market Overview

  • 3.1. Overview of Global Diagnostic Market
  • 3.2. SWOT Analysis of Diagnostic Industry
  • 3.3. Current Status of the Cancer Diagnostic Market
  • 3.4. Overview of CTC and CSC
    • 3.4.1. Current Status of the Market
    • 3.4.2. Future Potential
    • 3.4.3. Growth Opportunities
  • 3.5. Recent Breakthrough in CTC and CSC Research
  • 3.6. Drivers for CTC and CSC Market
  • 3.7. Restraints for CTC and CSC Market
  • 3.8. Opportunities for CTC and CSC Market

4. Circulating Tumor Cells (CTC)

  • 4.1. What are Circulating Tumor Cells
  • 4.2. Important Milestone in CTC Discovery
  • 4.3. Biology and Characteristics of CTCs
  • 4.4. CTC for Cancer Diagnostics
  • 4.5. CTCs Vs DTCs
  • 4.6. CTC Enrichment Methods
    • 4.6.1. PCR-based Analysis
      • 4.6.1.1. RT-PCR
      • 4.6.1.2. RT-qPCR
    • 4.6.2. Cytometric Analysis
      • 4.6.2.1. CellSearch
      • 4.6.2.2. LSC
      • 4.6.2.3. FAST
      • 4.6.2.4. Flow cytometry
      • 4.6.2.5. CTC-Chip
      • 4.6.2.6. Elispot
      • 4.6.2.7. FISH
  • 4.7. Cell Search System
  • 4.8. Advantages and Disadvantages of CTC Enrichment Techniques
  • 4.9. CTC Utility in Diagnosis and Detection
  • 4.10. Predictions made on CTC detection and analysis
  • 4.11. Improvements in the detection of CTCs and DTCs
  • 4.12. Worldwide Growth in the Prevalence of Cancer

5. Cancer Stem Cells (CSC)

  • 5.1. What are Cancer Stem Cell (CSCs)
  • 5.2. Current Cancer Diagnostics and Therapy
  • 5.3. Developing Cancer
  • 5.4. Metastasis
  • 5.5. Metastatic Cascade
  • 5.6. Mostly Affected Sites by Metastasis
  • 5.7. CTCs Vs DTCs
  • 5.8. Blood Description of patient with metastatic disease
  • 5.9. Comparison between CTCS and CSCs
  • 5.10. EMT and Three Classes of EMT
  • 5.11. Biology of CSCs
  • 5.12. Stem Cells Markers

6. Competitive Analysis

  • 6.1. Market Shares of Various CSC and CTC Research Products vendors
  • 6.2. CSC Research Focus
  • 6.3. Estimated Cancer Deaths, 2011
  • 6.4. New cancer cases by type (male and female) in the U.S., 2012 (estimated)
  • 6.5. Improvement in CTC Detection
  • 6.6. Breast Cancer Statistics and Facts
  • 6.7. Study of CTCs for primary vs metastatic disease
  • 6.8. Geographic Distribution of Market Survey Respondent Pool
  • 6.9. Cancer stem cell (CSC) markers, malignancies and
  • multimarker profiles
  • 6.10. Market Analysis and Methodologies

7. Geographical Analysis

  • 7.1. North America
  • 7.2. Europe
  • 7.3. Asia Pacific

8. Company Profiles

  • 8.1. Johnson & Johnson
    • 8.1.1. Company Overview
    • 8.1.2. Growth Strategy
    • 8.1.3. Recent Development
    • 8.1.4. SWOT Analysis
  • 8.2. Abbott Laboratories
    • 8.2.1. Company Overview
    • 8.2.2. Growth Strategy
    • 8.2.3. Recent Development
    • 8.2.4. SWOT Analysis
  • 8.3. Bristol-Myers Squibb (BMS)
    • 8.3.1. Company Overview
    • 8.3.2. Growth Strategy
    • 8.3.3. Recent Development
    • 8.3.4. SWOT Analysis
  • 8.4. Dexcom
    • 8.4.1. Company Overview
    • 8.4.2. Growth Strategy
    • 8.4.3. Recent Development
    • 8.4.4. SWOT Analysis
  • 8.5. Eli Lilly
    • 8.5.1. Company Overview
    • 8.5.2. Growth Strategy
    • 8.5.3. Recent Development
    • 8.5.4. SWOT Analysis
  • 8.6. GlaxoSmithKline
    • 8.6.1. Company Overview
    • 8.6.2. Growth Strategy
    • 8.6.3. Recent Development
    • 8.6.4. SWOT Analysis
  • 8.7. Glenmark Pharmaceuticals
    • 8.7.1. Company Overview
    • 8.7.2. Growth Strategy
    • 8.7.3. Recent Development
    • 8.7.4. SWOT Analysis
  • 8.8. Lupin
    • 8.8.1. Company Overview
    • 8.8.2. Growth Strategy
    • 8.8.3. Recent Development
    • 8.8.4. SWOT Analysis
  • 8.9. Roche
    • 8.9.1. Company Overview
    • 8.9.2. Growth Strategy
    • 8.9.3. Recent Development
    • 8.9.4. SWOT Analysis
  • 8.10. Sanofi
    • 8.10.1. Company Overview
    • 8.10.2. Growth Strategy
    • 8.10.3. Recent Development
    • 8.10.4. SWOT Analysis
Show More
Pricing